MADRIGAL PHARMACEUTICALS INC (MDGL) Stock Overview
NASDAQ:MDGL - US5588681057 - Common Stock
MDGL Key Statistics, Chart & Performance
The current stock price of MDGL is 424.655 USD. In the past month the price increased by 44.31%. In the past year, price increased by 71.92%.
MDGL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.69 | 368.29B | ||
| AMGN | AMGEN INC | 13.18 | 154.71B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 141.69B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.98 | 99.82B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.91 | 62.47B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.50B | ||
| ARGX | ARGENX SE - ADR | 76.03 | 43.13B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.03 | 35.49B | ||
| INSM | INSMED INC | N/A | 28.23B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.59B | ||
| NTRA | NATERA INC | N/A | 22.35B | ||
| BIIB | BIOGEN INC | 8.57 | 20.11B |
Related stock screener links
About MDGL
Company Profile
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 528 full-time employees. The company went IPO on 2007-02-06. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Company Info
MADRIGAL PHARMACEUTICALS INC
200 Barr Harbor Dr Ste 400
West Conshohocken PENNSYLVANIA 19428 US
CEO: Paul A. Friedman
Employees: 528
Phone: 14043809263
MADRIGAL PHARMACEUTICALS INC / MDGL FAQ
What is the stock price of MADRIGAL PHARMACEUTICALS INC today?
The current stock price of MDGL is 424.655 USD. The price decreased by -0.05% in the last trading session.
What is the ticker symbol for MADRIGAL PHARMACEUTICALS INC stock?
The exchange symbol of MADRIGAL PHARMACEUTICALS INC is MDGL and it is listed on the Nasdaq exchange.
On which exchange is MDGL stock listed?
MDGL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MADRIGAL PHARMACEUTICALS INC stock?
23 analysts have analysed MDGL and the average price target is 454.67 USD. This implies a price increase of 7.07% is expected in the next year compared to the current price of 424.655. Check the MADRIGAL PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MADRIGAL PHARMACEUTICALS INC worth?
MADRIGAL PHARMACEUTICALS INC (MDGL) has a market capitalization of 9.47B USD. This makes MDGL a Mid Cap stock.
How many employees does MADRIGAL PHARMACEUTICALS INC have?
MADRIGAL PHARMACEUTICALS INC (MDGL) currently has 528 employees.
What are the support and resistance levels for MADRIGAL PHARMACEUTICALS INC (MDGL) stock?
MADRIGAL PHARMACEUTICALS INC (MDGL) has a support level at 298.28. Check the full technical report for a detailed analysis of MDGL support and resistance levels.
Is MADRIGAL PHARMACEUTICALS INC (MDGL) expected to grow?
The Revenue of MADRIGAL PHARMACEUTICALS INC (MDGL) is expected to grow by 401.73% in the next year. Check the estimates tab for more information on the MDGL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MADRIGAL PHARMACEUTICALS INC (MDGL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MDGL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MDGL, evaluating the profitability, health, valuation and growth aspects
- MADRIGAL PHARMACEUTICALS INC (MDGL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MADRIGAL PHARMACEUTICALS INC (MDGL) Sales and EPS estimates to see what analysts future expectations are.
- MADRIGAL PHARMACEUTICALS INC (MDGL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MADRIGAL PHARMACEUTICALS INC (MDGL) Insider and Institutional Ownership to learn about the owners and their transactions.
- MADRIGAL PHARMACEUTICALS INC (MDGL) Stock Chart to make your own analysis
- MADRIGAL PHARMACEUTICALS INC (MDGL) Latest news and press-releases to stay up to date.
Does MADRIGAL PHARMACEUTICALS INC (MDGL) stock pay dividends?
MDGL does not pay a dividend.
When does MADRIGAL PHARMACEUTICALS INC (MDGL) report earnings?
MADRIGAL PHARMACEUTICALS INC (MDGL) will report earnings on 2025-10-29, before the market open.
What is the Price/Earnings (PE) ratio of MADRIGAL PHARMACEUTICALS INC (MDGL)?
MADRIGAL PHARMACEUTICALS INC (MDGL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.85).
What is the Short Interest ratio of MADRIGAL PHARMACEUTICALS INC (MDGL) stock?
The outstanding short interest for MADRIGAL PHARMACEUTICALS INC (MDGL) is 19.35% of its float. Check the ownership tab for more information on the MDGL short interest.
MDGL Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to MDGL. When comparing the yearly performance of all stocks, MDGL is one of the better performing stocks in the market, outperforming 94.08% of all stocks.
MDGL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MDGL. MDGL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MDGL Financial Highlights
Over the last trailing twelve months MDGL reported a non-GAAP Earnings per Share(EPS) of -12.85. The EPS increased by 49.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.76% | ||
| ROE | -40.5% | ||
| Debt/Equity | 0.17 |
MDGL Forecast & Estimates
23 analysts have analysed MDGL and the average price target is 454.67 USD. This implies a price increase of 7.07% is expected in the next year compared to the current price of 424.655.
For the next year, analysts expect an EPS growth of 51.76% and a revenue growth 401.73% for MDGL